{"filing":{"accession_number":"0001062822-26-000112","cik":"0001062822","ticker":"LXRX","company_name":"LEXICON PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"lxrx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282226000112/lxrx-20260806.htm"},"events":[{"id":25383,"run_id":23032,"accession_number":"0001062822-26-000112","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Lexicon Pharmaceuticals issued a press release on August 6, 2026, reporting financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenues of $0.7 million, net loss of $31.8 million ($0.07 per share), and key pipeline updates. The filing explicitly states \"On August 6, 2026, we issued a press release to report our financial results for the quarter ended June 30, 2026\" with the press release attached as Exhibit 99.1, which is the standard format for an earnings release disclosure under Item 2.02.","company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26190,"accession_number":"0001062822-26-000112","item_number":"2.02","item_title":"Results of Operation and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Lexicon Pharmaceuticals issued a press release on August 6, 2026, reporting financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenues of $0.7 million, net loss of $31.8 million ($0.07 per share), and key pipeline updates. The filing explicitly states \"On August 6, 2026, we issued a press release to report our financial results for the quarter ended June 30, 2026\" with the press release attached as Exhibit 99.1, which is the standard format for an earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:36:56.229551+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26190,"accession_number":"0001062822-26-000112","item_number":"2.02","item_title":"Results of Operation and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Lexicon Pharmaceuticals issued a press release on August 6, 2026, reporting financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenues of $0.7 million, net loss of $31.8 million ($0.07 per share), and key pipeline updates. The filing explicitly states \"On August 6, 2026, we issued a press release to report our financial results for the quarter ended June 30, 2026\" with the press release attached as Exhibit 99.1, which is the standard format for an earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:36:56.229551+00:00","company_name":"LEXICON PHARMACEUTICALS, INC.","ticker":"LXRX","filing_date":"2026-08-06"}]}